Biotech News

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

SIGA Technologies Inc (SIGA)SIGA Technologies IncFDA / regulatory

Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of Smallpox Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of Smallpox

Related news

SPROSpero Therapeutics2026-06-17 17:36 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

SIGASIGA Technologies Inc2026-10-29 11:30 EST

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

SIGASIGA Technologies Inc2026-08-06 20:01 EST

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

COCPCocrystal Pharma2026-06-03 11:00 EST

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

ANTXAN2 Therapeutics2026-08-24 11:00 EST

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SIGA Technologies Inc

SIGA Technologies is a specialty pharmaceutical company best known for its antiviral countermeasure portfolio, especially against orthopox and smallpox-related threats. Its story is tied to government procurement and biodefense demand.

Recent company news

Stock data

Close
2.65 USD
Market cap
309.85M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States